
==== Front
Immunohorizons
Immunohorizons
IH
ImmunoHorizons
2573-7732
AAI

39172025
immunohorizons_2400032
10.4049/immunohorizons.2400032
On the Horizon
From Womb to World: Exploring the Immunological Connections between Mother and Child
https://orcid.org/0000-0002-6602-3374
Cherayil Bobby J. * †
Jain Nitya * † ‡
* Mucosal Immunology and Biology Research Center, Mass General for Children, Charlestown, MA
† Department of Pediatrics, Harvard Medical School, Boston, MA
‡ Center for Computational and Integrative Biology, Mass General Brigham, Boston, MA
Address correspondence and reprint request to: Dr. Nitya Jain, Mass General Brigham, 114 16th Street, Charlestown, MA 02129. E-mail address: njain@mgh.harvard.edu
8 2024
22 8 2024
8 8 552562
20 3 2024
23 7 2024
Copyright © 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the CC BY 4.0 Unported license.

Abstract

Mother and child are immunologically interconnected by mechanisms that we are only beginning to understand. During pregnancy, multiple molecular and cellular factors of maternal origin are transferred across the placenta and influence the development and function of the fetal and newborn immune system. Altered maternal immune states arising from pregnancy-associated infections or immunizations have the potential to program offspring immune function in ways that may have long-term health consequences. In this study, we review current literature on the impact of prenatal infection and vaccination on the developing immune system, highlight knowledge gaps, and look to the horizon to envision maternal interventions that could benefit both the mother and her child.
==== Body
pmcIntroduction

The maternal immune system undergoes significant modifications during pregnancy to establish tolerance toward the semiallogeneic fetus while maintaining the ability to protect the mother and developing fetus from infections. Numerous factors, such as nutrition, stress, and hormones, regulate maternal immune status during pregnancy, and readers are directed to excellent reviews that cover these topics (1–4). For the most part, any event that impacts maternal immunity can have an influence on pregnancy itself as well as on the developing fetal immune system. The early-life immune system develops in functional layers (5). Given the developmental plasticity inherent in these early-life processes, it may be appropriate to extend the principles of the Developmental Origins of Health and Disease hypothesis (6) to the immune system. This theory posits that exposure to environmental stimuli during critical periods of prenatal development can have profound effects on an individual’s short- and long-term health. For example, adverse conditions in the uterine environment can lead to alterations in fetal endocrine and metabolic activity, resulting in altered growth and irreversible changes in the structure and function of vital organs (7–9). Subsequent environmental influences during infancy and childhood further reinforce the risk of disease later in life (10–12).

Exposure to infectious agents during pregnancy can affect the developing fetal immune system and impact subsequent newborn immune responses to infections and vaccinations (13). Understanding the mechanisms of maternal influence on offspring immunity is crucial for formulating strategies to mitigate the long-term health impacts of adverse developmental immune imprinting. In this article, we provide an overview of the various ways in which a pregnant female can communicate immunologically with her developing offspring (Fig. 1). We focus on the impact of pregnancy-associated infections on these channels of communication and how they impact offspring immunity. Last, we discuss current maternal immunization strategies and highlight areas of uncertainty and future research priorities.

FIGURE 1. The mother–infant dyad: vertically transferred immunity.

Offspring immunity is influenced by several vertically transferred maternal factors, including Ab, cytokines, Ag, microbes, and cells. Maternal immune states arising from pregnancy-associated infections and immunizations can impact these pathways and have long-term consequences on offspring health, including susceptibility to infections and immune-mediated diseases as well as neurodevelopment. The figure was created using BioRender.com.

Mechanisms mediating maternal effects on offspring immunity

Mother and offspring constitute a single interconnected unit during pregnancy and for about 1 y after birth. Through the course of this period, an array of maternal molecules and cells are transferred to the fetus and infant, with some providing passive antimicrobial protection and others influencing the development and function of the baby’s own immune defenses (14). The best studied of the molecules are maternal Abs: IgG, which is transported across the placenta into the fetal circulation and confers passive humoral immunity on the newborn infant for 3–6 mo (15), and IgA, which is conveyed to the infant through breast milk and helps in defending against intestinal infection and in shaping the gut microbiota (16). Other transplacentally transferred maternal molecules that can affect the offspring immune system include inflammatory mediators, Ags, nutrients, and microbiota-derived components and metabolites. Constituents of breast milk apart from IgA can also influence offspring immunity. They include immunomodulatory cytokines such as TGF-β and specific oligosaccharides that promote the development of a healthy gut microbiota and inhibit pathogen colonization (17, 18).

In addition to soluble molecules, maternal cells can make their way across the placenta and into breast milk (19–21). The effects of this mode of maternal–offspring interaction are not well understood, especially in humans. In mouse studies, transplacentally transferred cells from the mother have been implicated in the development of tolerance to noninherited maternal Ags in the fetus (14). Similarly, animal experiments have shown that maternal cells in breast milk can survive transit through the neonatal gut and even traffic to distal sites, but their influence on offspring immune function remains rather speculative (22).

A final mechanism by which the mother can affect the infant’s immune system is by transfer of her microbiota at the time of delivery (5). The fetus does not have a resident microbial community and is first exposed to microorganisms during birth. The newborn’s tissues are initially colonized by organisms derived from either the mother’s intestinal and genital tracts (if the delivery is vaginal) or from the mother’s skin and the hospital environment (if the delivery is by cesarean section) (23, 24). These pioneer microbes set the stage for subsequent waves of colonization until a stable, adult-type microbiota is established by the age of 2–3 y. Studies in mice and humans over the last 10–20 y have provided compelling evidence that the microbiota has profound effects on the development, phenotype, and function of multiple immune cell populations (25). These effects, in turn, can influence the ability to respond to antigenic challenges and susceptibility to infectious and immune-mediated diseases (26–28). Thus, variations in the mother’s microbiota can have a significant impact on the offspring’s immune capabilities.

Effects of maternal infection on offspring immunity

Infections during pregnancy, caused by viruses, bacteria, fungi, or parasites, collectively represent a common clinical problem that can vary in severity from the relatively trivial to the life-threatening (29, 30). They can have obvious, sometimes severe, effects on the health of the fetus as well as more subtle influences on the structure and function of developing fetal tissues and organ systems. The immune system is not exempt from such developmental disturbances, and there is emerging evidence that maternal infection and, more broadly, the microbial milieu during pregnancy can have significant effects on immune function in the offspring. Each of the connections between the mother and the fetal/infant immune system can be perturbed by maternal infection or other microbial exposure, and such perturbations have the potential to alter offspring immune functions, either in the short term or more persistently. Studies in mice and humans provide evidence of these effects, as described in the sections that follow.

Abs

Any time a pregnant woman is infected or otherwise exposed to an antigenic stimulus, she will generate an Ab response, including Ag-specific IgG and possibly IgA. Her repertoire of circulating Abs also reflects her earlier antigenic exposures. IgG can cross the placenta into the fetal circulation, and, interestingly, recent studies in mice indicate that maternal IgG undergoes pregnancy-associated changes in glycan structure that enhance its antimicrobial capabilities in the newborn offspring (31). Secretory IgA produced by the mother is released into breast milk and transmitted to the newborn during suckling. Because the mother’s circulating IgG and breast milk IgA are largely directed against the Ags to which she has been exposed, including those derived from microbial pathogens and her own microbiota, the Abs represent vehicles for transmitting maternal immunological experience to the baby.

Transport of maternal IgG across the placenta requires the neonatal Fc receptor expressed on the syncytiotrophoblast, but other Fc receptors also probably contribute to the process (14, 32, 33). Transfer is generally proportional to serum IgG concentration (up to a point; see below). It is greatest during the third trimester of pregnancy and is affected by IgG subclass and by Ab glycosylation status (14, 15, 33, 34). Maternal infection can impair transplacental movement of IgG directed against a variety of Ags, an effect that has been documented in a large number of clinical studies, especially in the context of malaria and HIV infections (35–39). One factor contributing to this effect is the elevation of serum IgG that can occur in both malaria and HIV infection (35, 36, 38). A concentration above 15 g/L decreases the fraction of circulating IgG transported across the placenta, possibly as a result of saturation of transport mechanisms (14). But additional mechanisms are likely to be involved because maternal infection–associated decreases in transplacental Ab transfer can occur in the absence of hypergammaglobulinemia and can be selective for IgG of specific subclasses or Ag specificities (40). Maternal infection with HIV, SARS-CoV-2, and Plasmodium falciparum all show such subclass- and Ag-specific effects on IgG transport (40–42). This phenomenon may be explained by the changes in Ab glycosylation that are known to occur in the context of infectious and noninfectious inflammation and that can affect IgG–Fc receptor interactions (42–44).

Because maternal Abs represent an important source of protection for the first 3–6 mo of life, a significant decrease in transplacental IgG transfer can compromise antimicrobial defense in the infant (14, 15). However, transplacentally transferred maternal Abs can also interfere with the offspring’s own humoral responses, including to vaccination, either by masking vaccine Ags or by attenuating B cell activation through binding to specific Fc receptors (45, 46). It is even possible that the interaction of maternal IgG with Fc receptors on infant immune cells could influence offspring immunity more broadly. Such effects need to be considered when designing maternal immunization strategies. Finally, it is worth noting that some maternal Abs can have adverse effects on the fetus and newborn, such as Abs directed against the dengue virus or against offspring paternal Ags (14). In such situations, infection-associated impairment of IgG transport across the placenta may be beneficial.

Although IgG is generally considered to be the only isotype that is actively transported across the placenta, studies in mice indicate that maternal IgE can make its way into the fetal circulation in a complex with IgG (47, 48). The maternal IgE can bind to fetal mast cells, setting the stage for the later development of skin and airway allergic responses on exposure to the relevant Ag. A similar phenomenon may occur in humans because allergen-specific IgE can be detected in umbilical cord blood and IgE has been found in association with human fetal skin mast cells (47, 49). Whether the transplacental movement of maternal IgE is affected by maternal infection or immune activation remains to be determined.

In addition to IgG and IgE, breast milk IgA is the other maternal Ab that can influence offspring immunity. Secretory IgA, produced by maternal plasma cells in the mammary gland, is transported into breast milk by the polyimmunoglobulin receptor and exerts its effects in the gastrointestinal tract of the suckling infant (16). It provides protection against enteropathogens and plays important roles in shaping the infant’s gut microbiota. As discussed in greater detail below, microbiota composition can have significant effects on various aspects of immune function. Maternal infection and vaccination have been shown to increase the quantity of breast milk IgA specific for the infecting pathogen or vaccine, but whether these states of immune activation have a similar effect on IgA directed against other Ags is unclear (50–56). The limited data available suggest that maternal infection and other states of immune activation do not alter IgA quantity in milk (57).

Cytokines

Activation of a pregnant woman’s immune system as a result of infection or other stimuli is usually associated with increased expression of various inflammatory cytokines, some being produced by fetal cells, whereas others are secreted by maternal cells and then transferred across the placenta into the fetal circulation. These cytokines may influence the development and function of the fetal immune system either positively or negatively, sometimes with long-lasting consequences. There are several examples of this type of fetal immune “training” that have been observed in clinical studies and mouse experiments, and the action of specific cytokines such as type I and type II IFNs, IL-6, IL-10, and TGF-β has been implicated in some cases (58).

One of the early examples of long-term programming of the fetal immune system by maternal inflammation derives from experiments in which pregnant mice were injected with the TLR3 ligand polyinosinic:polycytidylic acid [poly(I:C)] to mimic the effects of a viral infection. In addition to behavioral traits mimicking certain aspects of autism, the adult offspring of the poly(I:C)-injected mothers displayed multiple abnormalities of the immune system, including an overall hyperinflammatory phenotype characterized by a decrease in regulatory T cells, an increase in Th17 cells, and alterations in myeloid cell populations (59). The long-lived nature of the immune abnormalities induced in offspring by this type of maternal immune activation (MIA) has focused attention on the effects of inflammation on fetal hematopoietic stem and precursor cells (HSPCs). Indeed, fetal HSPCs can directly sense inflammatory mediators, including pathogen-associated molecular patterns and various cytokines, and respond by proliferating and changing their differentiation potential (60). Because a subset of fetal HSPCs contribute to adult hematopoiesis, alterations induced in these cells by maternal inflammation can have lasting effects in the offspring (60). Illustrating such effects, the type I IFN that results from MIA with poly(I:C) in mice has been shown to lead to expansion and hyperactivation of innate-like B lymphocyte populations in the progeny, with corresponding elevation of natural Ab levels in the peritoneal cavity and increased production of IL-10 by peritoneal B-1 cells following in vitro stimulation (61). Similarly, infection of pregnant mice with Toxoplasma gondii led to expansion and altered differentiation potential of HSPCs in the fetal liver, with injected IFN-γ reproducing some of the effects (62). Even more strikingly, a recent (as yet unpublished) study showed that injecting pregnant mouse dams with poly(I:C) reprogrammed fetal HSPCs, leading to increased numbers and hyperresponsiveness of group 2 innate lymphoid cells in the lungs of the adult progeny (López D. A., A. Griffin, L. M. Aguilar, C.-D. Rice, E. J. Myers, K. J. Warren, R. Welner, and A. E. Beaudin, manuscript posted on bioRxiv, DOI: 10.1101/2023.11.20.567899). Moreover, the expanded and hyperresponsive group 2 innate lymphoid cells contributed to a heightened airway allergic response (D. A. López et al., manuscript posted on bioRxiv, DOI: 10.1101/2023.11.20.567899).

HSPCs are not the only fetal stem cells that are affected by maternal inflammation. When pregnant mice were infected with an attenuated strain of Yersinia, which was cleared quickly and never crossed the placenta, the adult offspring had increased numbers of Th17 cells in the intestinal lamina propria, making them more resistant to oral Salmonella infection but also more susceptible to the induction of noninfectious colitis (63). The mechanism of this effect was found to involve epigenetic reprogramming of fetal intestinal epithelial stem cells by maternal IL-6, which promoted the enhanced expression of antimicrobial genes and genes influencing Th differentiation. The results suggest that similar effects may occur in other tissues, a possibility that will no doubt be addressed in future studies.

Breast milk contains a number of cytokines that can vary widely in concentration from one individual to the next and, in some cases, with lactation stage (64–66). It is particularly rich in members of the TGF-β family, which are present in biologically relevant amounts. The cytokines may be produced by maternal leukocytes and epithelial cells, although definitive data addressing the exact source are currently lacking. Several of the cytokines, particularly TGF-β, have been shown or postulated to modulate immune function in the infant in various ways. Abnormalities in this process have been linked to the development of inflammatory diseases such as necrotizing enterocolitis, but the evidence is largely circumstantial. Maternal infection has varying effects on breast milk cytokine concentrations. In a large study of Peruvian mothers of low-birth-weight neonates, peripartum infection (unspecified febrile illness or urinary tract infection) was associated with significantly lower concentrations of some cytokines in colostrum (66). On the other hand, at least some studies of maternal HIV or SARS-CoV-2 infection have demonstrated significant elevations of breast milk TGF-β2 and other cytokines (67, 68). Whether any of these maternal infection–associated changes in breast milk cytokine levels have effects on the infant immune system remains to be clarified.

Ags

Ags to which a pregnant individual is exposed, from the environment or as the result of infection or vaccination, can make their way across the placenta and prime the fetal immune system (59, 69). The exact mechanisms that allow the transplacental movement of Ag are not well understood and could involve transport in the free form, as part of a complex with IgG (facilitated by neonatal Fc receptor) or in association with cells or microvesicles. The details of how Ag is presented to and sensed by fetal adaptive immune cells are also not clear. Regardless, both clinical studies and experiments in mice have provided evidence, in the form of newborn Ag-specific Abs or T cell responses, that lymphocytes can be sensitized by prenatal exposure to Ag, including in the context of several types of maternal infection (58, 69). Such sensitization can result in lymphocyte activation or tolerance, depending on circumstances, with corresponding effects on the offspring’s response when subsequently exposed to the Ag. Placental malaria infection, where malaria Ags gain access to the fetal circulation, is a valuable model to examine pathogen-specific fetal immune responses (70–73). For instance, in utero exposure to malaria Ags, as occurs in a significant fraction of pregnancies in endemic regions of Africa, has been reported to induce either a protective effector CD4+T cell response or a suppressive T-regulatory cell response, based on factors such as timing of exposure, relative fetal immune maturation, and the presence of active placental infection (74). The offspring have increased malaria resistance or susceptibility, respectively, at least for the first few years after birth (70).

Microbiota

Studies in humans and mice carried out over the last couple of decades have provided evidence of the profound influence of the microbiota on the development and function of the immune system and on the occurrence of infectious and immune-mediated diseases (25–28). The maternal microbiome during pregnancy can also have significant impacts on immune system programming (75). The newborn’s microbiota is initially derived from the mother during birth, a process that represents a major mechanism mediating maternal influence on offspring immunity (23, 24). Plausible links can be made between maternal infection or immune activation, abnormalities of the mother’s and newborn’s microbiota, and infant immune function, but studies that have directly examined this chain of causality are hard to find. However, several investigations in both humans and mice have shown that antibiotic treatment of the mother during pregnancy, either presumed or documented to alter the microbiota composition, can affect the offspring’s immune capabilities or risk of infection and immune-mediated disease. For instance, a large birth cohort study from Denmark showed that children born to mothers treated with antibiotics during pregnancy had an elevated risk of infection-related hospitalization and that the risk increased with the number of antibiotics used and use close to birth (76). A recent meta-analysis of 31 clinical and animal studies supported this finding and extended the increased risk of pregnancy antibiotics to asthma and atopic dermatitis (77).

Cells

There are limited reports on the presence and functionality of maternal microchimeric cells (MMCs) in human infants, especially in relation to maternal infection and offspring disease susceptibility. High numbers of maternal memory T cells have been demonstrated in cord blood (78). In one study of a nested cohort in Tanzania, inflammatory placental malaria infection was associated with increased levels of cord blood MMCs that correlated with decreased symptomatic malaria in infected infants (79). This observation was similar to another study in American children that found the presence of MMCs in whole blood to be protective from later development of asthma (80). In a study of a Ugandan cohort, although P. falciparum parasitemia in the first half of pregnancy was also associated with increased prevalence of MMCs in cord blood, there was no association between MMC numbers in preparasitemia samples and first parasitemia samples in childhood, suggesting that acute infection may not alter the levels of microchimerism (81). Furthermore, although the malaria studies found an association between maternal infectious state and presence of MMCs in offspring, an analysis of a South African maternal–infant cohort found that HIV-exposed but uninfected children had fewer MMCs than HIV-unexposed children, and this correlated with an altered response to bacillus Calmette-Guérin vaccination (82). One explanation for these discordant observations might be the different levels of MIA and placental inflammation across cohorts that might contribute to altered MMC functional imprinting and trafficking.

In a study using an animal model of preconception infection with OVA-expressing Listeria, OVA-specific maternal T cells were shown to be transferred to the fetus during pregnancy (83). The presence of these chimeric T cells in offspring correlated with less severe disease following infectious challenge in early life. Maternal Ag-primed T cells may also be transferred through breastmilk, and in an animal model of preconceptual helminth infection, maternal CD4+ Th2 cells acquired from breast milk protected from the same nematode challenge in both early and later life (84). MMCs also protected from a neonatal CMV infection by promoting the differentiation of myeloid cells in the murine fetal bone marrow, although this was not studied in the context of maternal infection (85). MIA resulting from infectious challenge can also impact fetal brain development and long-term neurobehavioral processes (86). Viral infections, including rubella (87, 88) and influenza (89, 90), as well as bacterial infections, such as urinary tract infections (91, 92), during pregnancy are associated with autism spectrum disorder and other neurodevelopmental disorders (93). Although a role for MMCs was never considered in these human studies, MMCs have been detected in the offspring brain, and one study in animals reported that alterations in their number led to dysregulated offspring behaviors, although this was also not studied in the context of maternal inflammation (94).

Vaccinations and pregnancy

Early life represents a period of dramatic escalation in antigenic encounters by the relatively naive and still developing newborn immune system. It is not unexpected, therefore, that infectious morbidity and mortality are highest in the first weeks after birth (95). Maternal immunization during pregnancy represents a valuable strategy for protecting both the mother and her offspring from various infectious diseases. In addition to transfer of passive immunity to offspring, maternal vaccination has been associated with reduced rates of maternal morbidity and mortality, as well as improved birth outcomes, including reduced risks of preterm birth and low birth weight. We discuss these findings in the context of four vaccines currently approved for pregnant women: tetanus, diphtheria, acellular pertussis (Tdap), inactivated influenza, SARS-CoV-2, and respiratory syncytial virus (RSV).

Tdap vaccine

Pertussis, a highly contagious respiratory illness caused by Bordetella pertussis, is a significant public health concern, particularly for newborns who are too young to be vaccinated themselves. In 2011, the Tdap vaccine was recommended for pregnant women, to be administered at the beginning of the third trimester when transfer of IgG Ab via the placenta is at its highest. High titers of pertussis-specific IgG were detected in both the vaccinated mother and her newborn offspring (96). Ag-specific IgA was also detected in the colostrum of vaccinated mothers and in the newborns’ gut (97). Maternal Tdap vaccination during pregnancy was >90% effective in protecting against pertussis during the first 2 mo of life (98, 99). However, it was noted that Tdap vaccines do not fully protect the mother from infection (100). Furthermore, maternal Abs were linked to decreases in the newborn’s own immune response to subsequent pertussis vaccination as well as to heterologous polio and pneumococcus vaccine Ags (101–104). There is limited information on the impact of pregnancy-associated Tdap vaccination on cellular immune responses in offspring after pertussis primary and booster vaccination. One study found robust induction of Th1, Th2, and Th17 responses after acellular pertussis vaccination in infants (105), whereas another reported significant changes in the phenotype and cytokine responsiveness of infant PBMCs to B. pertussis as well as acellular pertussis vaccine Ags (106). Whether there is a direct impact of maternal Tdap vaccination on the developing human fetal adaptive immune system is not known. However, early studies in tetanus toxoid–vaccinated pregnant women identified toxoid-specific IgM Ab in cord blood, indicating fetal B cell sensitization (maternal IgM cannot cross the placenta) (107, 108). The impact of Tdap vaccination during pregnancy on the maternal microbiome as well as on the acquisition of MMCs by the offspring is entirely unknown.

Inactivated influenza vaccine

Influenza infection during pregnancy is associated with an increased risk of adverse maternal and neonatal outcomes, including preterm birth, low birth weight, neonatal death, and maternal complications such as pneumonia and respiratory failure (109). Both the inactivated and live influenza vaccines are currently not indicated for children below 6 mo of age. Thus, the quadrivalent inactivated influenza vaccine is recommended for all pregnant women, regardless of pregnancy trimester (110). However, flu vaccine administered in the late second or third trimester offers significant benefits to both mother and infant by providing humoral immunity that lasts 6–7 mo after vaccination and that is transferable to offspring across the placenta and via breast milk (111). A blunting effect of flu-specific maternal Abs on offspring responses has not been observed in humans (104). In a murine model of pregnancy-associated influenza immunization, high maternal Ab titers in offspring did not prevent neonatal B cell activation (112). Rather, the blunting effect was observed in the inability of germinal center B cells to become plasma and memory B cells. Thus, high titers of maternal Ab shaped the germinal center output and the Ag-specific B cell repertoire in murine offspring. Priming of the fetal immune system by maternal flu vaccination has been reported. Influenza-specific IgM Abs were detected in the cord blood of infants of immunized mothers (113). Using MHC tetramers to identify Ag-specific T cells, one study demonstrated the presence of memory T cells in the cord blood following vaccination against influenza during pregnancy (114). As with the Tdap vaccine, effects of flu vaccination on the maternal microbiome or the microchiome have not been investigated.

SARS-CoV-2 vaccine

The emergence of the COVID-19 pandemic, caused by the novel SARS-CoV-2 virus, has posed significant challenges to global public health, with pregnant women being particularly vulnerable because of potential complications associated with viral infections (115, 116). COVID-19 vaccines are recommended for pregnant women and have been shown to be effective in reducing hospitalization and poor outcomes after COVID-19 infection in infants (117). The mRNA vaccine elicits a robust Ag-specific Ab response that is detected in cord blood, breast milk, and serum of infants of vaccinated mothers (118–120). Of interest, unlike the flu and Tdap vaccines, mRNA-based COVID-19 vaccination during pregnancy did not elicit an IgM response in cord blood (121). There was also an absence of Spike mRNA or Ag in the placenta and cord blood, suggesting a lack of fetal priming in utero with this mode of vaccination (121, 122). COVID-19 vaccines have recently been approved for infants aged 6 mo and older. There are, however, as yet no published reports describing a blunting response to the vaccine after maternal COVID-19 immunization. The impact of maternal COVID-19 vaccine on the microbiome and MMCs is also unexplored.

RSV vaccine

RSV infection is a significant contributor to respiratory morbidity and mortality among infants, particularly those born prematurely or with underlying health conditions. Given the lack of effective treatments for RSV and the limitations of passive immunoprophylaxis with mAbs, maternal immunization has emerged as a promising approach to protect vulnerable infants from severe RSV-related illness. Recent data from clinical trials show that the RSVpreF Ag vaccine is safe and efficacious for use in pregnant women and prevents severe RSV disease in infants. Maternal RSV vaccine reduced the risk of severe RSV disease by 82% within 3 mo and by 69% within 6 mo after birth. The precise nature of the Ab response to RSV Ag in pregnant vaccinated women, as well as the titers achieved in offspring, are yet to be determined. Activation of fetal immunity by the vaccine also needs to be investigated.

Conclusions and Future Research Priorities

The study of transgenerational effects on immune function is relatively new, particularly in relation to humans. Some of the specific gaps in knowledge in this area have been alluded to in preceding sections. More broadly speaking, the field has thus far focused largely on the role of maternal Abs (transplacentally transferred IgG, breast milk IgA) and, more recently, on the maternal microbiota. Much less work has been done on other components of the maternal immune system that might influence offspring immunity: cells, cytokines, and additional soluble molecules. For instance, there is a significant paucity of information on MMCs and their effects in the fetus and infant. The same holds true for the multiple cytokines that are produced by maternal immune cells in the context of infection or other inflammatory stimulus and that have the potential to cross the placenta. Even with respect to transplacental transfer of IgG, the mechanisms involved in the selective impairment of transport of certain Ab subclasses or specificities that is seen in some maternal infections are not fully understood. We also do not have much insight into the effects of maternal infection on breast milk IgA. Recent advances in single-cell technologies and systems immunology, as well as increased access to human developmental tissue, will undoubtedly lead to important biological insights into these early-life processes (123).

Another area that has not received much attention and that is worth exploring is the sex specificity of maternal effects on fetal and infant immunity and how that might affect imprinting of offspring immune function by the maternal microbial environment. The bidirectional interaction between mother and fetus is influenced by the sex of the latter, both because of sex-specific differences in fetal physiology, including the physiology of the immune system, and because the mother responds differently to a male versus female fetus (124). Clinical studies have demonstrated that the sex of the fetus affects obstetric outcomes, including the occurrence of complications such as gestational diabetes and pregnancy-induced hypertension (125, 126). Whether fetal sex is a factor in imprinting of the developing immune system by maternal microbial exposure and the molecular mechanisms involved are issues that are yet to be clarified.

The inclusion of pregnant women in clinical trials evaluating vaccine safety and efficacy has been historically limited, leading to gaps in knowledge regarding the optimal vaccination strategies for this population. Vaccination during pregnancy confers numerous benefits to the mother and her offspring. However, high levels of vaccine-induced maternally derived Abs can blunt the infant’s own response to vaccination. Strategies to bypass these “blunting” effects need to be explored and may include the use of different adjuvants as well as altering the route of vaccination. There is also a paucity of information on the nonspecific effects (NSEs) of vaccines administered during pregnancy. Live vaccines are typically associated with beneficial NSEs on all-cause childhood mortality, but nonlive vaccines can have detrimental NSEs (127). Although live vaccines are currently not recommended during pregnancy, nonlive vaccines such as the influenza H1N1 vaccine have been shown to enhance susceptibility to unrelated infections in females (128). The consequences of maternal innate immune activation triggered by vaccines during pregnancy on offspring immunity remains unexplored.

The maternal influence on offspring immunity represents a potential therapeutic opportunity. It raises the possibility that manipulating the mother’s environmental exposures during pregnancy might be a way to program the fetal/neonatal immune system to modify susceptibility to infection or other types of disease. Pregnancy vaccination is one example of such an intervention, but one could envision extending the idea to other approaches, such as the administration of specific probiotics or other microbial products. The development and implementation of such strategies to “educate” early-life immunity could have significant long-term benefits for individual and public health.

Disclosures

The authors have no financial conflicts of interest.

HSPC hematopoietic stem and precursor cell

MIA maternal immune activation

MMC maternal microchimeric cell

NSE nonspecific effect

poly(I:C) polyinosinic:polycytidylic acid

RSV respiratory syncytial virus

Tdap tetanus, diphtheria, acellular pertussis
==== Refs
References

1 Macpherson, A. J., M. G. de Aguero, S. C. Ganal-Vonarburg. 2017. How nutrition and the maternal microbiota shape the neonatal immune system. Nat. Rev. Immunol. 17 : 508–517.28604736
2 Palmer, A. C. 2011. Nutritionally mediated programming of the developing immune system. Adv. Nutr. 2 : 377–395.22332080
3 Piccinni, M. P., C. Scaletti, E. Maggi, S. Romagnani. 2000. Role of hormone-controlled Th1- and Th2-type cytokines in successful pregnancy. J. Neuroimmunol. 109 : 30–33.10969178
4 Schumacher, A., S. D. Costa, A. C. Zenclussen. 2014. Endocrine factors modulating immune responses in pregnancy. Front. Immunol. 5 : 196.24847324
5 Jain, N. 2020. The early life education of the immune system: moms, microbes and (missed) opportunities. Gut Microbes 12 : 1824564.33043833
6 Gluckman, P. D., M. A. Hanson, C. Cooper, K. L. Thornburg. 2008. Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 359 : 61–73.18596274
7 Wang, H.-H., C.-L. Zhou, M. Lv, Q. Yang, J.-X. Li, M. Hou, J. Lin, X.-M. Liu, Y.-T. Wu, J.-Z. Sheng, . 2018. Prenatal high estradiol exposure induces sex-specific and dietarily reversible insulin resistance through decreased hypothalamic INSR. Endocrinology 159 : 465–476.29155986
8 Magalhães, E. S. D S., M. D. B. B. Méio, F. M. Peixoto-Filho, S. Gonzalez, A. C. C. da Costa, M. E. L. Moreira. 2020. Pregnancy-induced hypertension, preterm birth, and cord blood adipokine levels. Eur. J. Pediatr. 179 : 1239–1246.32062709
9 Schulte, S., F. Schreiner, M. Plamper, C. Kasner, M. Gruenewald, P. Bartmann, R. Fimmers, M. F. Hartmann, S. A. Wudy, B. Stoffel-Wagner, . 2020. Influence of prenatal environment on androgen steroid metabolism in monozygotic twins with birthweight differences. J. Clin. Endocrinol. Metab. 105 : dgaa480.32717093
10 Su, Y. M., G. R. Lv, J. X. Xie, Z. H. Wang, H. T. Lin. 2013. Maternal hypoxia increases the susceptibility of adult rat male offspring to high-fat diet-induced nonalcoholic fatty liver disease. Endocrinology 154 : 4377–4387.24002036
11 Wahlqvist, M. L., S. A. Krawetz, N. S. Rizzo, M. G. Dominguez-Bello, L. M. Szymanski, S. Barkin, A. Yatkine, R. A. Waterland, J. A. Mennella, M. Desai, . 2015. Early-life influences on obesity: from preconception to adolescence. Ann. N. Y. Acad. Sci. 1347 : 1–28.26037603
12 Vandyousefi, S., S. E. Whaley, E. M. Widen, F. M. Asigbee, M. J. Landry, R. Ghaddar, J. N. Davis. 2019. Association of breastfeeding and early exposure to sugar-sweetened beverages with obesity prevalence in offspring born to mothers with and without gestational diabetes mellitus. Pediatr. Obes. 14 : e12569.31389196
13 Dauby, N., T. Goetghebuer, T. R. Kollmann, J. Levy, A. Marchant. 2012. Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect. Dis. 12 : 330–340.22364680
14 Jennewein, M. F., B. Abu-Raya, Y. Jiang, G. Alter, A. Marchant. 2017. Transfer of maternal immunity and programming of the newborn immune system. Semin. Immunopathol. 39 : 605–613.28971246
15 Clements, T., T. F. Rice, G. Vamvakas, S. Barnett, M. Barnes, B. Donaldson, C. E. Jones, B. Kampmann, B. Holder. 2020. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. Front. Immunol. 11 : 1920.33013843
16 Donald, K., C. Petersen, S. E. Turvey, B. B. Finlay, M. B. Azad. 2022. Secretory IgA: linking microbes, maternal health, and infant health through human milk. Cell Host Microbe 30 : 650–659.35550668
17 Sprenger, N., H. L. P. Tytgat, A. Binia, S. Austin, A. Singhal. 2022. Biology of human milk oligosaccharides: from basic science to clinical evidence. J. Hum. Nutr. Diet. 35 : 280–299.35040200
18 Tarrant, I., B. B. Finlay. 2023. Human milk oligosaccharides: potential therapeutic aids for allergic diseases. Trends Immunol. 44 : 644–661.37438187
19 Molès, J.-P., E. Tuaillon, C. Kankasa, A.-S. Bedin, N. Nagot, A. Marchant, J. M. McDermid, P. Van de Perre. 2018. Breastmilk cell trafficking induces microchimerism-mediated immune system maturation in the infant. Pediatr. Allergy Immunol. 29 : 133–143.29197124
20 Jonsson, A. M., M. Uzunel, C. Gotherstrom, N. Papadogiannakis, M. Westgren. 2008. Maternal microchimerism in human fetal tissues. Am. J. Obstet. Gynecol. 198 : 325 e321–325.e6.
21 Mold, J. E., J. Michaëlsson, T. D. Burt, M. O. Muench, K. P. Beckerman, M. P. Busch, T.-H. Lee, D. F. Nixon, J. M. McCune. 2008. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 322 : 1562–1565.19056990
22 Laouar, A. 2020. Maternal leukocytes and infant immune programming during breastfeeding. Trends Immunol. 41 : 225–239.32057705
23 Browne, H. P., Y. Shao, T. D. Lawley. 2022. Mother-infant transmission of human microbiota. Curr. Opin. Microbiol. 69 : 102173.35785616
24 Bogaert, D., G. J. van Beveren, E. M. de Koff, P. Lusarreta Parga, C. E. Balcazar Lopez, L. Koppensteiner, M. Clerc, R. Hasrat, K. Arp, M. L. J. N. Chu, . 2023. Mother-to-infant microbiota transmission and infant microbiota development across multiple body sites. Cell Host Microbe 31 : 447–460 e446.36893737
25 Ansaldo, E., T. K. Farley, Y. Belkaid. 2021. Control of immunity by the microbiota. Annu. Rev. Immunol. 39 : 449–479.33902310
26 Lynn, D. J., S. C. Benson, M. A. Lynn, B. Pulendran. 2022. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nat. Rev. Immunol. 22 : 33–46.34002068
27 Miyauchi, E., C. Shimokawa, A. Steimle, M. S. Desai, H. Ohno. 2023. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat. Rev. Immunol. 23 : 9–23.35534624
28 Donald, K., B. B. Finlay. 2023. Early-life interactions between the microbiota and immune system: impact on immune system development and atopic disease. Nat. Rev. Immunol. 23 : 735–748.37138015
29 Megli, C. J., C. B. Coyne. 2022. Infections at the maternal-fetal interface: an overview of pathogenesis and defence. Nat. Rev. Microbiol. 20 : 67–82.34433930
30 Kumar, M., M. Saadaoui, S. Al Khodor. 2022. Infections and pregnancy: effects on maternal and child health. Front. Cell. Infect. Microbiol. 12 : 873253.35755838
31 Erickson, J. J., S. Archer-Hartmann, A. E. Yarawsky, J. L. C. Miller, S. Seveau, T.-Y. Shao, A. L. Severance, H. Miller-Handley, Y. Wu, G. Pham, . 2022. Pregnancy enables antibody protection against intracellular infection. Nature 606 : 769–775.35676476
32 Pyzik, M., K. M. K. Sand, J. J. Hubbard, J. T. Andersen, I. Sandlie, R. S. Blumberg. 2019. The neonatal Fc receptor (FcRn): a misnomer? Front. Immunol. 10 : 1540.31354709
33 Rosenberg, Y. J., T. Ordonez, U. S. Khanwalkar, P. Barnette, S. Pandey, I. M. Backes, C. E. Otero, B. S. Goldberg, A. R. Crowley, D. A. Leib, . 2023. Evidence for the role of a second Fc-binding receptor in placental IgG transfer in nonhuman primates. mBio 14 : e0034123.36946726
34 Jennewein, M. F., I. Goldfarb, S. Dolatshahi, C. Cosgrove, F. J. Noelette, M. Krykbaeva, J. Das, A. Sarkar, M. J. Gorman, S. Fischinger, . 2019. Fc glycan-mediated regulation of placental antibody transfer. Cell 178 : 202–215.e14.31204102
35 de Moraes-Pinto, M. I., F. Verhoeff, L. Chimsuku, P. J. Milligan, L. Wesumperuma, R. L. Broadhead, B. J. Brabin, P. M. Johnson, C. A. Hart. 1998. Placental antibody transfer: influence of maternal HIV infection and placental malaria. Arch. Dis. Child. Fetal Neonatal Ed. 79 : F202–F205.10194992
36 Okoko, B. J., L. H. Wesumperuma, M. O. Ota, M. Pinder, W. Banya, S. F. Gomez, K. P. McAdam, A. C. Hart. 2001. The influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a rural West African population. J. Infect. Dis. 184 : 627–632.11494168
37 Moro, L., A. Bardají, T. Nhampossa, I. Mandomando, E. Serra-Casas, B. Sigaúque, P. Cisteró, V. S. Chauhan, C. E. Chitnis, J. Ordi, . 2015. Malaria and HIV infection in Mozambican pregnant women are associated with reduced transfer of antimalarial antibodies to their newborns. J. Infect. Dis. 211 : 1004–1014.25271267
38 Atwell, J. E., B. Thumar, L. J. Robinson, R. Tobby, P. Yambo, M. Ome-Kaius, P. M. Siba, H. W. Unger, S. J. Rogerson, C. L. King, . 2016. Impact of placental malaria and hypergammaglobulinemia on transplacental transfer of respiratory syncytial virus antibody in Papua New Guinea. J. Infect. Dis. 213 : 423–431.26238686
39 Alonso, S., M. Vidal, G. Ruiz-Olalla, R. González, C. Jairoce, M. N. Manaca, M. Vázquez-Santiago, R. Balcells, A. Vala, M. Rupérez, . 2021. HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women. J. Infect. 82 : 45–57.33636218
40 Alonso, S., M. Vidal, G. Ruiz-Olalla, R. González, M. N. Manaca, C. Jairoce, M. Vázquez-Santiago, R. Balcells, A. Vala, M. Rupérez, . 2021. Reduced placental transfer of antibodies against a wide range of microbial and vaccine antigens in HIV-infected women in Mozambique. Front. Immunol. 12 : 614246.33746958
41 Atyeo, C., K. M. Pullen, E. A. Bordt, S. Fischinger, J. Burke, A. Michell, M. D. Slein, C. Loos, L. L. Shook, A. A. Boatin, . 2021. Compromised SARS-CoV-2-specific placental antibody transfer. Cell 184 : 628–642.e10.33476549
42 Bordt, E. A., L. L. Shook, C. Atyeo, K. M. Pullen, R. M. De Guzman, M.-C. Meinsohn, M. Chauvin, S. Fischinger, L. J. Yockey, K. James, . 2021. Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses. Sci. Transl. Med. 13 : eabi7428.34664987
43 Alter, G., T. H. M. Ottenhoff, S. A. Joosten. 2018. Antibody glycosylation in inflammation, disease and vaccination. Semin. Immunol. 39 : 102–110.29903548
44 Irvine, E. B., G. Alter. 2020. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology 30 : 241–253.32103252
45 Otero, C. E., S. N. Langel, M. Blasi, S. R. Permar. 2020. Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries. PLoS Pathog. 16 : e1009010.33211756
46 Xu, H., B. Heyman. 2020. IgG-mediated suppression of antibody responses: hiding or snatching epitopes? Scand. J. Immunol. 92 : e12921.32594540
47 Msallam, R., J. Balla, A. P. S. Rathore, H. Kared, B. Malleret, W. A. A. Saron, Z. Liu, J. W. Hang, C. A. Dutertre, A. Larbi, . 2020. Fetal mast cells mediate postnatal allergic responses dependent on maternal IgE. Science 370 : 941–950.33122426
48 Bundhoo, A., S. Paveglio, E. Rafti, A. Dhongade, R. S. Blumberg, A. P. Matson. 2015. Evidence that FcRn mediates the transplacental passage of maternal IgE in the form of IgG anti-IgE/IgE immune complexes. Clin. Exp. Allergy 45 : 1085–1098.25652137
49 Sybilski, A. J., A. Doboszynska, B. Samolinski. 2009. Total and antigen-specific IGE levels in umbilical cord blood. Eur. J. Med. Res. 14 Suppl 4 : 233–236.20156762
50 Pickering, L. K., A. L. Morrow, I. Herrera, M. O’Ryan, M. K. Estes, S. E. Guilliams, L. Jackson, S. Carter-Campbell, D. O. Matson. 1995. Effect of maternal rotavirus immunization on milk and serum antibody titers. J. Infect. Dis. 172 : 723–728.7658064
51 Munoz, F. M., J. A. Englund, C. C. Cheesman, M. L. Maccato, P. M. Pinell, M. H. Nahm, E. O. Mason, C. A. Kozinetz, R. A. Thompson, W. P. Glezen, . 2001. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 20 : 826–837.11738746
52 Obaro, S. K., H. E. Deubzer, V. O. Newman, R. A. Adegbola, B. M. Greenwood, D. C. Henderson. 2004. Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy. Pediatr. Infect. Dis. J. 23 : 1023–1029.15545857
53 McGuire, M. K., A. Z. Randall, A. E. Seppo, K. M. Järvinen, C. L. Meehan, D. Gindola, J. E. Williams, D. W. Sellen, E. W. Kamau-Mbuthia, E. W. Kamundia, . 2020. Multipathogen analysis of IgA and IgG antigen specificity for selected pathogens in milk produced by women from diverse geographical regions: the INSPIRE study. Front. Immunol. 11 : 614372.33643297
54 Pace, R. M., J. E. Williams, K. M. Järvinen, C. L. Meehan, M. A. Martin, S. H. Ley, C. Barbosa-Leiker, A. Andres, L. Yeruva, M. B. Belfort, . 2021. Milk from women diagnosed with COVID-19 does not contain SARS-CoV-2 RNA but has persistent levels of SARS-CoV-2-specific IgA antibodies. Front. Immunol. 12 : 801797.35003130
55 Olearo, F., L.-S. Radmanesh, N. Felber, R. von Possel, P. Emmerich, N. Pekarek, S. Pfefferle, D. Nörz, G. Hansen, A. Diemert, . 2022. Anti-SARS-CoV-2 antibodies in breast milk during lactation after infection or vaccination: a cohort study. J. Reprod. Immunol. 153 : 103685.36029724
56 Wachman, E. M., J. Snyder-Cappione, J. Devera, J. Boateng, Y. Dhole, K. Clarke, R. R. Yuen, S. E. Parker, J. Hunnewell, R. Ferraro, . 2023. Maternal, infant, and breast milk antibody response following COVID-19 infection in early versus late gestation. Pediatr. Infect. Dis. J. 42 : e70–e76.36729773
57 Demers-Mathieu, V., G. Mathijssen, C. Dapra, D. M. Do, E. Medo. 2021. Active free secretory component and secretory IgA in human milk: do maternal vaccination, allergy, infection, mode of delivery, nutrition and active lifestyle change their concentrations? Pediatr. Res. 89 : 795–802.32434213
58 Apostol, A. C., K. D. C. Jensen, A. E. Beaudin. 2020. Training the fetal immune system through maternal inflammation—a layered hygiene hypothesis. Front. Immunol. 11 : 123.32117273
59 Hsiao, E. Y., S. W. McBride, J. Chow, S. K. Mazmanian, P. H. Patterson. 2012. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc. Natl. Acad. Sci. U. S. A. 109 : 12776–12781.22802640
60 Tseng, N. A., A. E. Beaudin. 2023. The impact of prenatal inflammation on hematopoietic development. Curr. Opin. Hematol. 30 : 130–136.37254855
61 López, D. A., A. C. Apostol, E. J. Lebish, C. H. Valencia, M. C. Romero-Mulero, P. V. Pavlovich, G. E. Hernandez, E. C. Forsberg, N. Cabezas-Wallscheid, A. E. Beaudin, . 2022. Prenatal inflammation perturbs murine fetal hematopoietic development and causes persistent changes to postnatal immunity. Cell Rep. 41 : 111677.36417858
62 López, D. A., K. S. Otsuka, A. C. Apostol, J. Posada, J. C. Sánchez-Arcila, K. D. Jensen, A. E. Beaudin. 2023. Both maternal IFNgamma exposure and acute prenatal infection with Toxoplasma gondii activate fetal hematopoietic stem cells. EMBO J. 42 : e112693.37259639
63 Lim, A. I., T. McFadden, V. M. Link, S.-J. Han, R.-M. Karlsson, A. Stacy, T. K. Farley, D. S. Lima-Junior, O. J. Harrison, J. V. Desai, . 2021. Prenatal maternal infection promotes tissue-specific immunity and inflammation in offspring. Science 373 : eabf3002.34446580
64 Nolan, L. S., O. B. Parks, M. Good. 2019. A review of the immunomodulating components of maternal breast milk and protection against necrotizing enterocolitis. Nutrients 12 : 14.31861718
65 Andres, S. F., B. Scottoline, M. Good. 2023. Shaping infant development from the inside out: bioactive factors in human milk. Semin. Perinatol. 47 : 151690.36581527
66 Zambruni, M., A. Villalobos, A. Somasunderam, S. Westergaard, M. Nigalye, C. G. Turin, J. Zegarra, S. Bellomo, E. Mercado, T. J. Ochoa, . 2017. Maternal and pregnancy-related factors affecting human milk cytokines among Peruvian mothers bearing low-birth-weight neonates. J. Reprod. Immunol. 120 : 20–26.28399439
67 Mabaya, L., H. T. Matarira, D. M. Tanyanyiwa, C. Musarurwa, J. Mukwembi. 2021. Levels of total antioxidant capacity, sCD14, and TGF-beta2 in breast milk plasma of HIV-infected and HIV-uninfected lactating women. Breastfeed. Med. 16 : 821–826.34010029
68 Sánchez García, L., N. Gómez-Torres, F. Cabañas, R. González-Sánchez, M. López-Azorín, M. T. Moral-Pumarega, D. Escuder-Vieco, E. Cabañes-Alonso, I. Castro, C. Alba, . 2021. Immediate pre-partum SARS-CoV-2 status and immune profiling of breastmilk: a case-control study. Front. Immunol. 12 : 720716.34381462
69 Wilcox, C. R., C. E. Jones. 2018. Beyond passive immunity: is there priming of the fetal immune system following vaccination in pregnancy and what are the potential clinical implications? Front. Immunol. 9 : 1548.30061881
70 Odorizzi, P. M., P. Jagannathan, T. I. McIntyre, R. Budker, M. Prahl, A. Auma, T. D. Burt, F. Nankya, M. Nalubega, E. Sikyomu, . 2018. In utero priming of highly functional effector T cell responses to human malaria. Sci. Transl. Med. 10 : eaat6176.30333241
71 Tassi Yunga, S., A. K. Kayatani, J. Fogako, R. J. I. Leke, R. G. F. Leke, D. W. Taylor. 2017. Timing of the human prenatal antibody response to Plasmodium falciparum antigens. PLoS One 12 : e0184571.28950009
72 Metenou, S., A. L. Suguitan, Jr., C. Long, R. G. Leke, D. W. Taylor. 2007. Fetal immune responses to Plasmodium falciparum antigens in a malaria-endemic region of Cameroon. J. Immunol. 178 : 2770–2777.17312120
73 Callaway, P. C., L. A. Farrington, M. E. Feeney. 2021. Malaria and early life immunity: competence in context. Front. Immunol. 12 : 634749.33679787
74 Feeney, M. E. 2020. The immune response to malaria in utero. Immunol. Rev. 293 : 216–229.31553066
75 Koren, O., L. Konnikova, P. Brodin, I. U. Mysorekar, M. C. Collado. 2024. The maternal gut microbiome in pregnancy: implications for the developing immune system. Nat. Rev. Gastroenterol. Hepatol. 21 : 35–45.38097774
76 Miller, J. E., C. Wu, L. H. Pedersen, N. de Klerk, J. Olsen, D. P. Burgner. 2018. Maternal antibiotic exposure during pregnancy and hospitalization with infection in offspring: a population-based cohort study. Int. J. Epidemiol. 47 : 561–571.29415232
77 Gestels, T., Y. Vandenplas. 2023. Prenatal and perinatal antibiotic exposure and long-term outcome. Pediatr. Gastroenterol. Hepatol. Nutr. 26 : 135–145.37214166
78 Kanaan, S. B., H. S. Gammill, W. E. Harrington, S. C. De Rosa, P. A. Stevenson, A. M. Forsyth, J. Allen, E. Cousin, K. van Besien, C. S. Delaney, . 2017. Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant. Oncoimmunology 6 : e1311436.28638735
79 Harrington, W. E., S. B. Kanaan, A. Muehlenbachs, R. Morrison, P. Stevenson, M. Fried, P. E. Duffy, J. L. Nelson. 2017. Maternal microchimerism predicts increased infection but decreased disease due to Plasmodium falciparum during early childhood. J. Infect. Dis. 215 : 1445–1451.28329160
80 Thompson, E. E., R. A. Myers, G. Du, T. M. Aydelotte, C. J. Tisler, D. A. Stern, M. D. Evans, P. E. Graves, D. J. Jackson, F. D. Martinez, . 2013. Maternal microchimerism protects against the development of asthma. J. Allergy. Clin. Immunol. 132 : 39–44.23434286
81 Simon, N., J. Shallat, J. Houck, P. Jagannathan, M. Prahl, M. K. Muhindo, A. Kakuru, P. Olwoch, M. E. Feeney, W. E. Harrington, . 2021. Peripheral Plasmodium falciparum infection in early pregnancy is associated with increased maternal microchimerism in the offspring. J. Infect. Dis. 224 : 2105–2112.34010401
82 Balle, C, . 2022. Factors influencing maternal microchimerism throughout infancy and its impact on infant T cell immunity. J. Clin. Invest. 132 : e148826.35550376
83 Yüzen, D., C. Urbschat, S. Schepanski, K. Thiele, P. C. Arck, H.-W. Mittrücker. 2023. Pregnancy-induced transfer of pathogen-specific T cells from mother to fetus in mice. EMBO Rep. 24 : e56829.37610043
84 Darby, M. G., A. Chetty, D. Mrjden, M. Rolot, K. Smith, C. Mackowiak, D. Sedda, D. Nyangahu, H. Jaspan, K.-M. Toellner, . 2019. Pre-conception maternal helminth infection transfers via nursing long-lasting cellular immunity against helminths to offspring. Sci. Adv. 5 : eaav3058.31236458
85 Stelzer, I. A., C. Urbschat, S. Schepanski, K. Thiele, I. Triviai, A. Wieczorek, M. Alawi, D. Ohnezeit, J. Kottlau, J. Huang, . 2021. Vertically transferred maternal immune cells promote neonatal immunity against early life infections. Nat. Commun. 12 : 4706.34349112
86 Massrali, A., D. Adhya, D. P. Srivastava, S. Baron-Cohen, M. R. Kotter. 2022. Virus-induced maternal immune activation as an environmental factor in the etiology of autism and schizophrenia. Front. Neurosci. 16 : 943903.35757530
87 Berger, B. E., A. M. Navar-Boggan, S. B. Omer. 2011. Congenital rubella syndrome and autism spectrum disorder prevented by rubella vaccination—United States, 2001–2010. BMC Public Health 11 : 340.21592401
88 Chess, S., P. Fernandez, S. Korn. 1978. Behavioral consequences of congenital rubella. J. Pediatr. 93 : 699–703.702254
89 Mednick, S. A., M. O. Huttunen, R. A. Machon. 1994. Prenatal influenza infections and adult schizophrenia. Schizophr. Bull. 20 : 263–267.8085130
90 Brown, A. S., C. A. Schaefer, R. J. Wyatt, R. Goetz, M. D. Begg, J. M. Gorman, E. S. Susser. 2000. Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr. Bull. 26 : 287–295.10885631
91 Atladóttir, H. O., P. Thorsen, L. Østergaard, D. E. Schendel, S. Lemcke, M. Abdallah, E. T. Parner. 2010. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 40 : 1423–1430.20414802
92 Zerbo, O., Y. Qian, C. Yoshida, J. K. Grether, J. Van de Water, L. A. Croen. 2015. Maternal infection during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 45 : 4015–4025.24366406
93 Hall, M. B., D. E. Willis, E. L. Rodriguez, J. M. Schwarz. 2023. Maternal immune activation as an epidemiological risk factor for neurodevelopmental disorders: considerations of timing, severity, individual differences, and sex in human and rodent studies. Front. Neurosci. 17 : 1135559.37123361
94 Schepanski, S., M. Chini, V. Sternemann, C. Urbschat, K. Thiele, T. Sun, Y. Zhao, M. Poburski, A. Woestemeier, M.-T. Thieme, . 2022. Pregnancy-induced maternal microchimerism shapes neurodevelopment and behavior in mice. Nat. Commun. 13 : 4571.35931682
95 Wang, H., C. A. Liddell, M. M. Coates, M. D. Mooney, C. E. Levitz, A. E. Schumacher, H. Apfel, M. Iannarone, B. Phillips, K. T. Lofgren, . 2014. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 : 957–979.24797572
96 Leuridan, E., N. Hens, N. Peeters, L. de Witte, O. Van der Meeren, P. Van Damme. 2011. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr. Infect. Dis. J. 30 : 608–610.21206396
97 Demers-Mathieu, V., R. K. Huston, A. M. Markell, E. A. McCulley, R. L. Martin, D. C. Dallas. 2021. Impact of pertussis-specific IgA, IgM, and IgG antibodies in mother’s own breast milk and donor breast milk during preterm infant digestion. Pediatr. Res. 89 : 1136–1143.32599609
98 Baxter, R., J. Bartlett, B. Fireman, E. Lewis, N. P. Klein. 2017. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics 139 : e20164091.28557752
99 Tessier, E., H. Campbell, S. Ribeiro, N. K. Fry, C. Brown, J. Stowe, N. Andrews, M. Ramsay, G. Amirthalingam. 2021. Impact of extending the timing of maternal pertussis vaccination on hospitalized infant pertussis in England, 2014-2018. Clin. Infect. Dis. 73 : e2502–e2508.32569365
100 Kapil, P., T. J. Merkel. 2019. Pertussis vaccines and protective immunity. Curr. Opin. Immunol. 59 : 72–78.31078081
101 Maertens, K., R. N. Caboré, K. Huygen, N. Hens, P. Van Damme, E. Leuridan. 2016. Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study. Vaccine 34 : 142–150.26592142
102 Ladhani, S. N., N. J. Andrews, J. Southern, C. E. Jones, G. Amirthalingam, P. A. Waight, A. England, M. Matheson, X. Bai, H. Findlow, . 2015. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. Clin. Infect. Dis. 61 : 1637–1644.26374816
103 Halperin, S. A., J. M. Langley, L. Ye, D. MacKinnon-Cameron, M. Elsherif, V. M. Allen, B. Smith, B. A. Halperin, S. A. McNeil, O. G. Vanderkooi, . 2018. A randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response. Clin. Infect. Dis. 67 : 1063–1071.30010773
104 Zimmermann, P., K. P. Perrett, N. L. Messina, S. Donath, N. Ritz, F. R. M. van der Klis, N. Curtis. 2019. The effect of maternal immunisation during pregnancy on infant vaccine responses. EClinicalMedicine 13 : 21–30.31517260
105 Orije, M. R. P., I. García-Fogeda, W. Van Dyck, V. Corbière, F. Mascart, L. Mahieu, N. Hens, P. Van Damme, N. Cools, B. Ogunjimi, . 2022. Impact of maternal pertussis antibodies on the infants’ cellular immune responses. Clin. Infect. Dis. 75 : 442–452.34849638
106 Rice, T. F., D. A. Diavatopoulos, Y. Guo, B. Donaldson, M. Bouqueau, A. Bosanquet, S. Barnett, B. Holder, B. Kampmann. 2021. Modification of innate immune responses to Bordetella pertussis in babies from pertussis vaccinated pregnancies. EBioMedicine 72 : 103612.34649076
107 Gill, T. J., C. F. Repetti, L. A. Metlay, B. S. Rabin, F. H. Taylor, D. S. Thompson, A. L. Cortese 3rd, 1983. Transplacental immunization of the human fetus to tetanus by immunization of the mother. J. Clin. Invest. 72 : 987–996.6886013
108 Vanderbeeken, Y., M. Sarfati, R. Bose, G. Delespesse. 1985. In utero immunization of the fetus to tetanus by maternal vaccination during pregnancy. Am. J. Reprod. Immunol. Microbiol. 8 : 39–42.4025666
109 Rasmussen, S. A., D. J. Jamieson, T. M. Uyeki. 2012. Effects of influenza on pregnant women and infants. Am. J. Obstet. Gynecol. 207 : S3–S8.22920056
110 Lagousi, T., D. Gkentzi, M. Geropeppa, P. Tsagkli, V. Spoulou. 2022. Protecting the offspring, the gift of maternal immunization: current status and future perspectives. Vaccines (Basel) 10 : 1953.36423047
111 Cuningham, W., N. Geard, J. E. Fielding, S. Braat, S. A. Madhi, M. C. Nunes, L. M. Christian, S.-Y. Lin, C.-N. Lee, K. Yamaguchi, . 2019. Optimal timing of influenza vaccine during pregnancy: a systematic review and meta-analysis. Influenza Other Respir. Viruses 13 : 438–452.31165580
112 Vono, M., C. S. Eberhardt, F. Auderset, B. Mastelic-Gavillet, S. Lemeille, D. Christensen, P. Andersen, P.-H. Lambert, C.-A. Siegrist. 2019. Maternal antibodies inhibit neonatal and infant responses to vaccination by shaping the early-life B cell repertoire within germinal centers. Cell Rep. 28 : 1773–1784.e5.31412246
113 Englund, J. A., IN. Mbawuike, H. Hammill, M. C. Holleman, B. D. Baxter, W. P. Glezen. 1993. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J. Infect. Dis. 168 : 647–656.8354906
114 Rastogi, D., C. Wang, X. Mao, C. Lendor, P. B. Rothman, R. L. Miller. 2007. Antigen-specific immune responses to influenza vaccine in utero. J. Clin. Invest. 117 : 1637–1646.17549258
115 Villar, J., S. Ariff, R. B. Gunier, R. Thiruvengadam, S. Rauch, A. Kholin, P. Roggero, F. Prefumo, M. S. do Vale, J. A. Cardona-Perez, . 2021. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 175 : 817–826.33885740
116 Knight, M., K. Bunch, N. Vousden, E. Morris, N. Simpson, C. Gale, P. O’Brien, M. Quigley, P. Brocklehurst, J. J. Kurinczuk, UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group. 2020. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ 369 : m2107.32513659
117 Carlsen, E. Ø., M. C. Magnus, L. Oakley, D. B. Fell, M. Greve-Isdahl, J. M. Kinge, S. E. Håberg. 2022. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern. Med. 182 : 825–831.35648413
118 Collier, A.-R. Y., K. McMahan, J. Yu, L. H. Tostanoski, R. Aguayo, J. Ansel, A. Chandrashekar, S. Patel, E. Apraku Bondzie, D. Sellers, . 2021. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA 325 : 2370–2380.33983379
119 Prabhu, M., E. A. Murphy, A. C. Sukhu, J. Yee, S. Singh, D. Eng, Z. Zhao, L. E. Riley, Y. J. Yang. 2021. Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet. Gynecol. 138 : 278–280.33910219
120 Shook, L. L., C. G. Atyeo, L. M. Yonker, A. Fasano, K. J. Gray, G. Alter, A. G. Edlow. 2022. Durability of anti-Spike antibodies in infants after maternal COVID-19 vaccination or natural infection. JAMA 327 : 1087–1089.35129576
121 Mithal, L. B., S. Otero, E. D. Shanes, J. A. Goldstein, E. S. Miller. 2021. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am. J. Obstet. Gynecol. 225 : 192–194.33812808
122 Male, V. 2022. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat. Rev. Immunol. 22 : 277–282.35304596
123 Webb, S., M. Haniffa. 2023. Large-scale single-cell RNA sequencing atlases of human immune cells across lifespan: possibilities and challenges. Eur. J. Immunol. 53 : e2250222.36826421
124 Baines, K. J., R. C. West. 2023. Sex differences in innate and adaptive immunity impact fetal, placental, and maternal health. Biol. Reprod. 109 : 256–270.37418168
125 Al-Qaraghouli, M., Y. M. V. Fang. 2017. Effect of fetal sex on maternal and obstetric outcomes. Front. Pediatr. 5 : 144.28674684
126 Broere-Brown, Z. A., M. C. Adank, L. Benschop, M. Tielemans, T. Muka, R. Gonçalves, W. M. Bramer, J. D. Schoufour, T. Voortman, E. A. P. Steegers, . 2020. Fetal sex and maternal pregnancy outcomes: a systematic review and meta-analysis. Biol. Sex Differ. 11 : 26.32393396
127 Aaby, P., C. S. Benn, K. L. Flanagan, S. L. Klein, T. R. Kollmann, D. J. Lynn, F. Shann. 2020. The non-specific and sex-differential effects of vaccines. Nat. Rev. Immunol. 20 : 464–470.32461674
128 Benn, C. S., A. B. Fisker, A. Rieckmann, S. Sorup, P. Aaby. 2020. Vaccinology: time to change the paradigm? Lancet Infect. Dis. 20 : e274–e283.32645296
